Vimarsana
Biggest News Aggregation in the World

Page 31 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Functional Impairment Increases Depression Risk in Psoriasis, Psoriatic Arthritis - Vimarsana News

Functional Impairment Increases Depression Risk in Psoriasis, Psoriatic Arthritis

A cross-sectional study of survey data shows more than 50% of psoriasis and over 60% of psoriatic arthritis patients have depressive symptoms, with results drawing a link between functional impairment and the likelihood of depressive symptoms.

Retinal Vein Occlusion Could Serve as Age-Dependent Risk Factor for Dementia - Vimarsana News

Retinal Vein Occlusion Could Serve as Age-Dependent Risk Factor for Dementia

New data suggests retinal vein occlusion in individuals under 75 years of age correlates with increased dementia risk, while those older than 75 have a reduced risk.

Smokeless Tobacco Use Linked to Increased Risk of Kidney Disease, Anemia - Vimarsana News

Smokeless Tobacco Use Linked to Increased Risk of Kidney Disease, Anemia

New research highlights the potential health risks associated with using smokeless tobacco, including anemia, hypertension, and chronic kidney disease.

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT - Vimarsana News

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 ...

Landmark Phase 3 MARIPOSA Study Shows - Vimarsana News

Landmark Phase 3 MARIPOSA Study Shows

Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in...